Bladder Cancer Glycan Detection via Capillary Electrophoresis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting bladder cancer in urine samples lack specificity and accuracy, with tumour heterogeneity making single biomarkers ineffective, and existing analytical methods often result in high false positive rates.
Innovation Solution
The method involves analyzing urine samples for elevated levels of the glycan lacto-N-neo-tetraose (nLc4) and other glycosphingolipids, which are specifically indicative of bladder cancer, using capillary gel electrophoresis coupled with laser-induced fluorescence detection (xCGE-LIF) to differentiate between cancerous and healthy samples, and employing peptides or antibodies specific to these glycans for treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If multiple biomarkers are used to detect bladder cancer, then detection accuracy is improved, but test complexity increases
Solution Approach 1:
The patent segments the complex detection task by identifying and analyzing specific glycan structures (nLc4, lactose, Gb3, Gb4) as separate biomarkers. Each glycan is analyzed independently through capillary gel electrophoresis, allowing the system to handle complexity through structured decomposition rather than treating all biomarkers uniformly.
Solution Approach 2:
The patent changes the detection parameters by using capillary gel electrophoresis with laser-induced fluorescence detection, which allows for the differentiation and quantification of specific glycan structures based on their electrical properties and fluorescence characteristics, enabling accurate detection without requiring complex multi-step analysis.
2Device complexity
If single biomarkers are used for bladder cancer detection, then test simplicity is maintained, but detection accuracy deteriorates due to tumour heterogeneity
Solution Approach 1:
The patent applies universality by selecting glycan structures that are universally expressed across different bladder cancer subtypes. The glycan markers (nLc4, lactose, Gb3, Gb4) are found to be present in various bladder cancer types, making them universally applicable biomarkers that can detect different tumour heterogeneities through a single analytical approach.
3Ease of operation
If existing analytical methods are used for urine analysis, then ease of operation is maintained, but false positive rate increases
Solution Approach 1:
The patent replaces conventional mechanical or chemical urine analysis methods with capillary gel electrophoresis coupled to laser-induced fluorescence detection. This substitution enables more precise differentiation between cancerous and non-cancerous samples by detecting specific glycan structures based on their electrophoretic mobility and fluorescence properties, thereby reducing false positives while maintaining operational ease.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a highly accurate and specific method for detecting bladder cancer with low false positives, allowing for effective treatment targeting the tumour-specific antigens, thereby improving diagnostic and therapeutic outcomes.
Implementation Method 1
capillary gel electrophoresis coupled with laser-induced fluorescence detection (xCGE-LIF)
Implementation Method 2
capillary gel electrophoresis coupled with laser-induced fluorescence detection (xCGE-LIF)
Data Source
Figure 1
Figure 1
Figure 1
AI summary
The invention provides an analytical method for detecting bladder cancer by analysing a urine sample for presence of a glycan tumour antigen, the presence of which has been identified to indicate bladder cancer. The analytical method has the advantage that the tumour antigen can be analysed in a urine sample and has a high accuracy for indicating presence of cancer in the urinary tract, especially bladder cancer, e.g. the method has a low rate of false positive results.